WASHINGTON — It’s a small update to a Food and Drug Administration policy first launched by the Obama administration, but top Trump health officials — and key congressional Republicans and drug makers — are nonetheless touting it as a central part of the Trump camp’s efforts to lower prescription drug prices.

On Tuesday, the FDA finalized guidance documents, released in draft form in mid-January 2017, making it clear that drug and device companies are allowed to share with insurers information that is not in the FDA-approved labeling. Insurers can use that information to determine how much they should pay for the drugs, FDA commissioner Scott Gottlieb said in a statement.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy